Table VIII.
Risk ratios for apremilast discontinuation
| Risk factor | Relative risk (CI) | P value |
|---|---|---|
| Female sex | 0.885 (0.662-1.182) | .4077 |
| Concomitant psoriatic arthritis | 1.095 (0.777-1.542) | .6046 |
| Age <40 years at start of treatment | 1.493 (1.111-2.007) | .007918∗ |
| BMI ≥30 | 0.576 (0.294-1.128) | .1075 |
| Previous biologic treatment | 1.269 (0.949-1.696) | .1083 |
| Palmar and/or plantar involvement | 0.986 (0.627-1.551) | .9526 |
| Scalp involvement | 1.228 (0.872-1.729) | .2396 |
| Nail involvement | 1.143 (0.821-1.593) | .4288 |
| Inverse involvement | 0.989 (0.616-1.590) | .9662 |
BMI, Body mass index; CI, confidence interval.
∗
Significant P values are in bold.